Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents

by L.P. Zanaga, N. Miotto, L.C. Mendes, R.S.B. Stucchi, A.G. Vigani

Recurrent hepatitis C treatment with direct acting antivirals – a real life study at a Brazilian liver transplant center

by L.P. Zanaga, A.G. Santos, E.C. Ataíde, I.F.S.F. Boin, R.S.B. Stucchi

Survival benefits of interferon-based therapy in patients with recurrent hepatitis C after orthotopic liver transplantation

by L.P. Zanaga, A.G. Vigani, R.N. Angerami, A. Giorgetti, C.A.F. Escanhoela, E.C. Ataíde, I.F.S.F. Boin, R.S.B. Stucchi

Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors

by N. Miotto, L.C. Mendes, L.P. Zanaga, E.S.L. Goncales, M.S.K. Lazarini, M.N. Pedro, F.L. Goncales Jr., R.S.B. Stucchi, A.G. Vigani
Published 2016-01-01